Determination of hypersensitivity to genotoxic agents among Escherichia coli single gene knockout mutants

DNA Repair

Volumn 9, Issue 9, 2010, Pages 949-957

  Becket, Elinne ^a   Chen, Frank ^a   Tamae, Cindy ^a   Miller, Jeffrey H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

5 Azacytidine; Cisplatin; Zebularine

Indexed keywords

6 CHLORO 9 [3 (2 CHLOROETHYL)AMINOPROPYLAMINO] 2 METHOXYACRIDINE; ANTIBIOTIC AGENT; AZACITIDINE; BLEOMYCIN; BROXURIDINE; CISPLATIN; METHOTREXATE; MUTAGENIC AGENT; TRIMETHOPRIM; ZEBULARINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DNA REPAIR; DRUG MECHANISM; DRUG POTENTIATION; ESCHERICHIA COLI; FOLATE METABOLISM; GENE IDENTIFICATION; GENOTOXICITY; HYPERSENSITIVITY; KNOCKOUT GENE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ESCHERICHIA COLI; GENE KNOCKOUT TECHNIQUES; MICROBIAL SENSITIVITY TESTS; MUTAGENS; MUTATION;

ESCHERICHIA COLI;

EID: 77955984309     PISSN: 15687864     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dnarep.2010.06.008     Document Type: Article

References (66)

1. Beck D.J., Brubaker R.R. Effect of cis-platinum (II) diamminodichloride on wild-type and deoxynucleic acid repair-deficient mutants of Escherichia coli. J. Bacteriol. 1973, 116:1247-1252.
2. Konishi H., Usui T., Sawada H., Uchino H., Kidani Y. Effects of anticancer platinum compounds on Escherichia coli strains with normal and defective DNA repair capacity. Gann. 1981, 72:627-630.
3. Fram R.J., Cusick P.S., Wilson J.M., Marinus M.G. Mismatch repair of cis-diamminedichloroplatinum(II)-induced DNA damage. Mol. Pharmacol. 1985, 28:51-55.
4. Popoff S.C., Beck D.J., Rupp w.D. repair of plasmid DNA damaged in vitro with cis- or trans-diamminedichloroplatinum(II) in Escherichia coli. Mutat. Res. 1987, 183:129-137.
5. Mello J.A., Trimmer E.E., Kartalou M., Essigman J.M. Confilcting roles of mismatch and nucleotide excision repair in cellular susceptibility to anticancer drugs. Nucleic Acids and Molecular Biology 1998, 249-274. Springer-Verlag, Heidelberg, Berlin. F. Eckstein, D.J.M. Liley (Eds.).
6. Zdraveski Z., Mello J.A., Marinus M.G., Essigmann J.M. Multiple pathways of recombination define cellular responses to cisplatin. Chem. Biol. 2000, 7:39-50.
7. Massey A., Offman J., Macpherson P., Karran P. DNA mismatch repair and acquired cisplatin resistance in E. coli and human ovarian carcinoma cells. DNA Repair 2003, 2:73-89.
8. Nowosielska A., Calmann M.A., Zdraveski Z., Essigmann J.M., Marinus M.G. Spontaneous and cisplatin-induced recombination in Escherichia coli. DNA Repair 2004, 3:719-728.
9. Calmann M.A., Marinus M.G. Differential effects of cisplatin and MNNG on dna mutants of Escherichia coli. Mutat. Res. 2005, 578:406-416.
10. Martin L.P., Hamilton T.C., Schilder R.J. Platinum resistance: the role of DNA repair pathways. Clin. Cancer Res. 2008, 14:1291-1295.
11. Moggs J.G., Szymkowski D.E., Yamada M., Karran P., Wood R.D. Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts. Nucleic Acids Res. 1997, 25:480-491.
12. Djit F.J., Fichtinger-Schepman A.M., Berends F., Reedijk J. Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient fibroblasts. Cancer Res. 1988, 48:6058-6062.
13. Koberle B., Masters J.R.W., Hartley J.A., wood R.D. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr. Biol. 1999, 9:273-276.
14. Vaismin A., Varchenko M., Umar A., Kunkel T.A., Risinger J.I., Barrett J.C., Hamilton T.C., Chaney S.G. Thee role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res. 1998, 58:3579-3585.
15. Ho Y.-P., Au-Yeung S.C.F., To K.K.W. Platinum-based anticancer agents: innovative design strategies and biological perspectives. Med. Res. Rev. 2003, 23:633-655.
16. Ozols R.F. Chemotherapy for advanced epithelial ovarian cancer. Hematol. Oncol. Clin. North Am. 1992, 6:879-894.
17. Burger R.M., Peisach J., Horwitz S.B. Activated bleomycin. A transient complex of drug, iron, and oxygen that degrades DNA. J. Biol. Chem. 1981, 256:11636-11644.
18. Povirk L.F., Han Y.H., Steighner R.J. Structure of bleomycin-induced DNA doubles-strand breaks: predominance of blunt ends and single-base 5' extensions. Biochemistry 1989, 28:5808-5814.
19. Curigliano G., Spitaleri G., Magni E., Lorizzo K., De Cobelli O., Locatelli M., Fumagalli L., Adamoil L., Cossu Rocca M., Verri E., De Pas T., Jereczek-Fossa B., Martinelli G., Goldhirsch A., Nolé F., Cisplatin etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors: efficacy and toxicity data from a retrospective study. J. Chemother. 2009, 21:687-692.
20. Kuruvilla J. Standard therapy of advanced Hodgkin lymphoma. Hematol. Am. Soc. Hematol. Educ. Program 2009, 497-506.
21. Galanski M., Jakupec M.A., Keppler B.K. Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr. Med. Chem. 2005, 12:2075-2094.
22. Rosenberg B., Van Camp L., Trosko J.E., Mansour V.H. Platinum compounds: a new class of antitumor agents. Nature 1969, 222:385-386.
23. Chu G. Cellular responses to cisplatin: the roles of DN binding proteins and DNA repair. J. Biol. Chem. 1994, 269:787-790.
24. Rosenberg B. Platinum complexes for the treatment of cancer: why the search goes on. Chemistry and Biochemistry of a Leading Anticancer Drug 1999, 1-27. Wiley-VCH, New York. B. Lippert (Ed.).
25. Ozols R.F. Ovarian cancer: new clinical approaches. Cancer Treat. Rev. 1991, 18:77-83.
26. Ohtsu A. Chemotherapy for metastatic gastric cancer: past, present, and future. J. Gastroenterol. 2008, 43:256-264.
27. Creech H.J., Preston R.K., Pek R.M., Hsie A.W. Mutagenicity and cytotoxicity of nineteen heterocyclic mustards (ICR compounds) in cultured mammalian cells. Cancer Res. 1979, 39:4875-4881.
28. Ferguson L.R., Denny W.A. Frameshift mutagenesis by acridines and other reversibly-binding DNA ligands. Mutagenesis 1990, 5:529-540.
29. Calos M.P., Miller J.H. Genetic and sequence analysis of frameshift mutations induced by ICR191. J. Mol. Biol. 1981, 153:39-64.
30. Cariello N.F., Keohavong P., Kat A.G., Thilly W.G. Molecular analysis of complex human cell populations: mutational spectra of MNNG and ICR191. Mutat. Res. 1990, 231:165-176.
31. Taft S.A., Liber H.L., Skopek T.R. Mutational spectrum of ICR191 at the hprt locus in human lymphoblastoid cells. Environ. Mol. Mutagen. 1994, 23:96-100.
32. Chen W.-D., Eshleman J.R., Aminoshariae M.R., Ma A.-H., Veloso N., Markowitz S.D., Sedwick W.D., Veigl M.L. Cytotoxicity and mutagenicity of frameshift-inducing agent ICR191 in mismatch repair-deficient colon cancer cells. JNCI 2000, 92:480-485.
33. Marquez V.E., Kelley J.A., Agbaria R., Ben-Kasus T., Cheng J.C., Yoo C.B., Jones P.A. Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. Ann. N. Y. Acad. Sci. 2005, 1058:246-254.
34. Levin D.E., Ames B.N. Classifying mutagens as to their specificity in causing the six possible transitions and transversions: a simple analysis using the Salmonella mutagenicity assay. Environ. Mutag. 1986, 8:9-28.
35. Cupples C.G., Miller J.H. A set of lacZ mutations in Escherichia coli that allow rapid detection of each of the six base substitutions. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:5345-5349.
36. Jackson Grusby L., Laird P.W., Magge Sn.N., Moeller B.J., Jaenisch R. Mutagenicity of 5-aza-2'-deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:4681-4685.
37. Lee G., Wolff E., Miller J.H. Mutagenicity of the cytidine analog zebularine in Escherichia coli. DNA Repair 2004, 3:155-161.
38. Gowher H., Jeltsch A. Mechanism of inhibition of DNA methyltransferases by cytidine analogs in cancer therapy. Cancer Biol. Ther. 2004, 3:10620-11068.
39. Yoo C.B., Jones P.A. Epigenetic therapy of cancer: past, present, and future. Nat. Rev. Drug Discov. 2006, 5:37-50.
40. Cheng J.C., Matsen C.B., Gonzales F.A., Ye W., Greer S., Marquez V.E., Jones P.A., Selker E.U. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J. Natl. Cancer Inst. 2003, 95:399-409.
41. Cheng J.C., Weisenberger D.J., Gonzales F.A., Gangning L., Zu G.L., Hu Y.G., Marquez V.E., Jones P.A. Continuous zebularine treatment effective sustains demethylation in human bladder cancer cells. Mol. Cell. Biol. 2004, 24:1270-1278.
42. Scott S.A., Lakshimikuttysamma A., Sheridan D.P., Sanche S.E., Geyer C.R., De Coteau J.F. Zebularine inhinits human acute myleloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression. Exp. Hematol. 2007, 35:263-273.
43. Herranz M., Martin-Caballero J., Fraga M.F., Ruiz-Cabello J., Flores J.M., Desco M., Marquez V.E., Esteller M. The novel DNA methylation inhibitor zebularine is effective against the development of T-cell lymphoma. Blood 2006, 107:1174-1177.
44. Zhou L., Cheng X., Connolly B.A., Dickman M.J., Hurd P.J., Hornby D.P. Zebularine, a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J. Mol. Biol. 2002, 23:591-599.
45. Carlow D., Wolfenden R. Substrate connectivity effects in the transition state for cytidine deaminase. Biochemistry 1998, 37:11873-11878.
46. Lemaire M., Momparler L.F., Raynal N.J.-M., Bernstein M.L., Momparler R.L. Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2'-deoxycytidine. Cancer Chemother. Pharmacol. 2009, 63:411-416.
47. Mancini W.R., Glaze E.R., Stetson P.L., Greenberg H.S. Sensitization of 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin cytotoxicity by 5-bromo-2'deoxyuridine in human glioma. J. Pharm. Exp. Ther. 1999, 289:1404-1409.
48. Greenberg H.S., Chandler W.F., Diaz R.F., Enzminger W.D., Junck L., Page M.A., Gabarski S.S., McKeever P., Hood T.W., Stetson P.L., Lichter A.S., Tankanow R. Intra-arterial bromodeoxyuridineradiosensitization and radiation in treatment of malignant astrocytomas. J. Neurosurg. 1988, 69:500-505.
49. Henderson J.P., Byun J., Takeshita J., Heinecke J. Phagocytes produce 5-chlorouracil and 5-bromouracil, two mutagenic products of myeloperoxidase, in human inflammatory tissue. J. Biol. Chem. 2003, 278:23522-23528.
50. Baba T., Ara T., Hasegawa M., Takai Y., Okumura Y., Baba M., Datsenko K.A., Tomita M., Wanner B.L., Mori H. Construction of Escherichia coli K-12 in-frame single-gene knockout mutants: the Keio collection. Mol. Syst. Biol. 2006, 2. (2006) 2006.0008.
51. Andrews J.M. Determination of minimum inhibitory concentrations. Antimicrob. Agents Chemother. 2001, 48:5-16.
52. Datsenko K.A., Wanner B.L. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:6640-6645.
53. Yu D., Ellis H.M., Lee E., Jenkins N.A., Copeland N.G., Court D.L. An efficient recombination system for chromosome engineering in Escherichia coli. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:5978-5983.
54. Tamae C., Liu A., Kim K., Sitz D., Hong J., Becket E., Bui A., Solaimani P., Tran K.P., Yang H., Miller J.H. Determination of antibiotic hypersensitivity among 4,000 single gene knockout mutants of Escherichia coli. J. Bacteriol. 2008, 190:5981-5988.
55. Miller J.H. A Short Course in Bacterial Genetics: A Laboratory Manual and Handbook for Escherichia coli and Related Bacteria 1992, Cold Spring Harbor Press, Cold Spring Harbor, New York.
56. Deutz W.A., Rüedi L., Hermann R., O'Connor K., Büchs J., Witholt B. Methods for intense aeration, growth, storage, and replication of bacterial strains in microtiter plates. Appl. Environ. Microbiol. 2000, 66:2641-2646.
57. Liu A., Tran L., Becket E., Lee K., Chinn L., Park E., Tran K., Miller J.H. Antibiotic sensitivity profiles determined with an Escherichia coli gene knockout collection: generating an antibiotic barcode. Antimicrob. Agents Chemother. 2010, 1393-1403.
58. Yamamoto N., Nakahigashi K., Nakamichi T., Yoshino M., Takai Y., Touda Y., Furubayashi A., Kinjyo S., Dose H., Hasegawa M., Datsenko K.A., Nakayashiki T., Tomita M., Wanner B.L., Mori H. Update on the KEIO collection of Escherichia coli single-gene deletion mutants. Mol. Syst. Biol. 2009, 5:335-338.
59. Nowosielska A., Marinus M.G. Cisplatin induces DNA double-strand break formation in Escherichia coli dam mutants. DNA Repair 2005, 4:773-781.
60. Kosa J.L., Zdravesky Z.Z., Currier S., Marinus M.G., Essigmannn J.M. RecN and RecG are required for Escherichia coli survival of Bleomycin-induced damage. Mutat. Res. 2004, 554:149-157.
61. Shiraishi K., Ogata Y., Hanada K., Kano y., Ikeda H. Roles of the DNA binding proteins H-NS and StpA in homologous recombination and repair of bleomycin-induced damage in Escherichia coli. Genes Genet. Syst. 2007, 82.:433-439.
62. Salem A.M.H., Nakano T., Takuwa M., Matoba N., Tsuboi T., Terato H., Yamamoto K., Yamada M., Nohmi T., Ide H. Genetic analysis of repair and damage tolerance mechanisms for DNA-protein cross-links in Escherichia coi. J. Bacteriol. 2009, 191:5657-5668.
63. Nowosielska A., Marinus M.G. DNA mismatch repair-induced double-strand breaks. DNA Repair 2008, 7:48-56.
64. Viswanathan M., Lovett S.T. Single-strand DNA-specific exonucleases in Escherichia coli. Roles in repair and mutation avoidance. Genetics 1998, 149:7-16.
65. Yeh P., Tschumi A.I., Kishony R. Functional classification of drugs by properties of their pairwise interactions. Nat. Genet. 2006, 28:489-494.
66. Sakoda T., Morizane R., Nakahara K., Enomoto Y., Nosaka A., Enomoto T., Kitano H. Chemotherapy with MTX, 5-FU, and CDGP for treatment of newly diagnosed head and neck cancer. Gan To Kagaku Ryoho 2009, 36:1451-1455.